Purpose: To investigate the anti-tumor activity and toxicity of the epidermal growth factor
receptor (EGFR) inhibitor gefitinib (ZD1839 or Iressa™; AstraZeneca Pharmaceuticals …

Purpose: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839];
AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase …

Purpose: A worldwide compassionate-use program has enabled> 42,000 patients with
advanced non-small cell lung cancer (NSCLC) to receive gefitinib treatment. Here we report …

Background The gefitinib compassionate-use programme has enabled> 39,000 patients
worldwide to receive gefitinib ('Iressa', ZD1839) treatment. This paper reports the outcome of …

Abstract Background Gefitinib (Iressa™, ZD1839) is an orally active, selective epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor. Phase I studies showed that it is well …

Gefitinib (ZD1839) is the most widely studied targeting agent in the area of non‐small‐cell
lung cancer (NSCLC). Gefitinib is an orally active epidermal growth factor receptor (EGFR) …

Background We describe 16 months' single-institution experience with gefitinib ('Iressa',
ZD1839) used as 'ultimum refugium'for pretreated non-small-cell lung cancer (NSCLC) …

Gefitinib (ZD1839, Iressa®), a selective drug inhibitor of the epidermal growth factor receptor
(EGFR) tyrosine kinase (TK), was recently approved for the treatment of patients with …

Purpose: To evaluate the efficacy of single-agent gefitinib (Iressa, ZD1839), an oral,
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as first-line …

Gefitinib (IressaTM), an orally-active tyrosine kinase inhibitor of the epidermal growth factor
receptor (EGFR), is the first approved molecular-targeted drug for the management of …